A Single-centre, Randomised, Positive-controlled, Single-dose, Dose-escalation Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of peginterferon Alfa-2a in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2015
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B; Hepatitis C
- Focus Biomarker; Pharmacodynamics; Pharmacokinetics
- 30 Jan 2012 Actual initiation date changed from Dec 2010 to Jan 2011 as reported by ClinicalTrials.gov.
- 30 Jan 2012 Actual patient number (39) added as reported by ClinicalTrials.gov.
- 30 Jan 2012 Actual end date (November 2011) added as reported by ClinicalTrials.gov.